Advanced Clinical Flow Cytometry Solutions for Oncology Research
Unlocking Cellular Insights with Precision and Expertise
Flow cytometry is becoming a critical tool in clinical trials, especially in immuno-oncology. Cell therapy such as CAR-T and CAR-NK often utilize flow cytometry to monitor the persistence and differentiation of the cells during treatment.
Multi-color flow cytometry assays allow for the identification and quantification of different cell types in a single heterogeneous sample and provide information about the frequency, phenotypes, or drug binding of specific cell populations.
Flow cytometry assays are a valuable endpoint in clinical trials to help assess a drug or cell therapy’s effect. Whole blood, PBMC, or bone marrow aspirate may be used as samples. We have extensive expertise in these areas:
- Immunophenotyping
- Receptor Occupancy Assays (ROA)
- Biomarker Assay Development
- Evaluation of Cell Surface and Intra-Cellular Markers
- Qualification/Validation of Flow Cytometry Assays
- Manufacturing Release Assays for Cell Therapies
- GLP Flow Cytometry
While it is not a requirement for every clinical flow cytometry assay, we are able to perform work in compliance with Good Laboratory Practice (GLP).
For example, standard TBNK panels are gated through CD45+ Lymphocytes to CD3+ cells, and then to CD4 (T Helper) and CD8 (T Effector) populations. B cells are identified as CD3-CD20+ and NK cells as CD3-CD16+. Examples of Non-Human Primate Panel A and Human Panel B TBNK results are shown below.
Request information about our Clinical Flow Cytometry Services
Contact our experts to help advance your drug development with TD2's Comprehensive Oncology Ecosystem.
Additional Resources
